{"id":"azd6094","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD73 is an enzyme involved in the production of adenosine, which plays a role in immune suppression. By inhibiting CD73, AZD6094 aims to reduce adenosine levels and enhance anti-tumor immune responses.","oneSentence":"AZD6094 is a small molecule inhibitor of the CD73 enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:26.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT03778229","phase":"PHASE2","title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-09","conditions":"Carcinoma","enrollment":367},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT03091192","phase":"PHASE3","title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-07-25","conditions":"Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms","enrollment":60},{"nctId":"NCT05620628","phase":"PHASE2","title":"Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)","status":"RECRUITING","sponsor":"Jeeyun Lee","startDate":"2023-01-05","conditions":"Stomach Cancer, Adenocarcinoma","enrollment":25},{"nctId":"NCT05043090","phase":"PHASE3","title":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-28","conditions":"Papillary Renal Cell Carcinoma","enrollment":148},{"nctId":"NCT03598244","phase":"PHASE1","title":"Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-27","conditions":"Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma","enrollment":41},{"nctId":"NCT02761057","phase":"PHASE2","title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-25","conditions":"Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":152},{"nctId":"NCT05261399","phase":"PHASE3","title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-08-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":324},{"nctId":"NCT02819596","phase":"PHASE2","title":"MEDI4736 Combinations in Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2016-05-03","conditions":"Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma","enrollment":69},{"nctId":"NCT03592641","phase":"PHASE2","title":"Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-25","conditions":"Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma","enrollment":5},{"nctId":"NCT02447406","phase":"PHASE1, PHASE2","title":"Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2015-04-30","conditions":"Advanced Gastric Adenocarcinoma","enrollment":7},{"nctId":"NCT02449551","phase":"PHASE2","title":"Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2016-02-10","conditions":"Advanced Gastric Adenocarcinoma","enrollment":16},{"nctId":"NCT02127710","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-30","conditions":"Papillary Renal Cell Cancer","enrollment":111},{"nctId":"NCT04675021","phase":"PHASE1","title":"Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-13","conditions":"Cancer","enrollment":8},{"nctId":"NCT02374645","phase":"PHASE1","title":"A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2015-04","conditions":"Non-Small Cell Lung Cancer","enrollment":64},{"nctId":"NCT03258515","phase":"PHASE1","title":"A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-06","conditions":"Solid Tumors","enrollment":45},{"nctId":"NCT02447380","phase":"PHASE2","title":"Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2017-07-10","conditions":"Advanced Gastric Adenocarcinoma","enrollment":2},{"nctId":"NCT03860948","phase":"PHASE1","title":"A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2019-04-16","conditions":"Bioequivalence","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":3,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":3,"reaction":"PYREXIA"},{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":2,"reaction":"ANAPHYLACTIC REACTION"},{"count":2,"reaction":"DRUG HYPERSENSITIVITY"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"NEUTROPHIL COUNT DECREASED"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Volitinib","Savolitinib","HMPL - 504"],"phase":"phase_2","status":"active","brandName":"AZD6094","genericName":"AZD6094","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD6094 is a small molecule inhibitor of the CD73 enzyme. Used for Metastatic non-small cell lung cancer, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}